Recent Press Releases

NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack

In draft guidance published today for consultation, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for preventing blood clots in people who have had a heart attack as a...

LEADING RESEARCHERS JOIN BIOGEN IDEC TO ADVANCE DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

–Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort– CAMBRIDGE, Mass., October 23, 2014, Biogen Idec (NASDAQ: BIIB)...

Lilly Reports Third-Quarter 2014 Results

Lilly Reports Third-Quarter 2014 Results NDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ -- Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and...

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal...

Celgene Reports Third Quarter 2014 Operating and Financial Results

Celgene Reports Third Quarter 2014 Operating and Financial Results - 2014 Total Revenue and Adjusted Diluted EPS Guidance Raised - Phase II Data on GED-0301 Presented at United European...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

INDIANAPOLIS and

Abbott Reports Third-Quarter 2014 Results

- Third-Quarter Adjusted EPS Above Previous Guidance Range, Including Results From Discontinued Operations Related to Mylan Transaction -

ABBOTT PARK, Ill.,

GSK CEO and CFO Interviewed on 2014 Q3 Results

LONDON, October 22, 2014 /PRNewswire/ --

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION PLEGRIDYTM Approved in the US and EU for Multiple Sclerosis ELOCTATETM Launched in the US for Hemophilia A Rollout of...

Roche invests for the future in its Basel site

Roche invests for the future in its Basel site Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.

Amgen Statement Regarding Third Point Investment

THOUSAND OAKS, Calif., Oct.

FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted...

ACTELION DELIVERS STRONG NINE MONTHS RESULTS

ACTELION DELIVERS STRONG NINE MONTHS RESULTS ALLSCHWIL/BASEL, SWITZERLAND - 21 October 2014 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2014. PRODUCT...

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND

ABBVIE ANNOUNCES NEW $5 BILLION STOCK REPURCHASE PROGRAM AND INCREASES DIVIDEND NORTH CHICAGO, Ill., Oct. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized...

Shire plc: AbbVie Terminates Offer for Shire

Shire plc: AbbVie Terminates Offer for Shire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 20, 2014